secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalyn Pharma Inc. (AVLN)
CIK:        0001540171
Form:       8-K
Filed at:   2026-09-16T20:13:18+00:00
Accession:  0001193125-26-393081
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Avalyn Pharma appoints former FDA director Robert Meyer to board
----------------------------------------------------------------

- Appointed Robert Meyer, M.D. as Class II director effective Sept 15, 2026; term expires at 2028 annual meeting.
- Meyer is independent under Nasdaq rules; ex-FDA drug evaluation director and Merck VP for global regulatory strategy.
- Eligible for $40,000 annual retainer; initial option for 31,182 shares vesting over 3 years plus annual 15,591-share grants.
- No arrangements or transactions requiring disclosure; signed standard indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/0001193125-26-393081-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540171/000119312526393081/ck0001540171-20260915.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-393081

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer